Metanx is an FDA-approved prescription medication used in patients with diabetic peripheral neuropathy as a dietary management for endothelial dysfunction. In late 2010, some pharmacies allegedly began distributing Neurpath-B as a Metanx generic substitute. However, the “generic” drug uses a different source of folate than the active compound found in Metanx, and according to the open letter Pamlab, the manufacturer of Metanx, an examination of Neurpath-B has revealed that the product is not therapeutically equivalent.
In late 2010, some pharmacies allegedly began distributing Neurpath-B as a Metanx generic substitute.
In addition, Neurpath-B states on the label that, “no representation is made as to generic status or bioequivalency.” Acella, the manufacturer of Neurpath-B, has done nothing to prevent pharmacies from offering the drug as a Metanx generic equivalent, Pamlab says. Allegedly, the price of Neurpath-B was intentionally set to mimic the price of Metanx.
Additionally, other medical foods and supplements have reportedly been replaced by pharmacists as generics for the branded, prescription drugs. These may include:
- Neevo DHA
Patients who were given “generic substitutes” for Metanx or any of the branded medical foods listed above may be eligible to recover the cost of their medication. To find out if you are eligible for compensation after receiving a medical food or Metanx substitute, fill out our free case evaluation form on the right.